PHARMAC performance 2014/15 Q3
Performance data to 31 March 2015
Our impacts: Impact on access to medicines
In the three months to 31 March 2015, PHARMAC added 2 pharmaceuticals to the Pharmaceutical Schedule. We estimate that these decisions will lead to $2,000 of gross expenditure and at least 1,600 patients receiving these medicines in the 2014/15 financial year.
From 1 July 2013, the Hospital Medicines List (HML) came into effect. In the third quarter, PHARMAC added one new listing and widened access to one pharmaceutical listed on the HML. Additional expenditure and savings were made through various tender and NPPA decisions.
Output Class 1: Decision-making
Measure: All funding decisions are supported by evidence and made using PHARMAC’s nine decision criteria.
Status: On track. All PHARMAC funding decision papers (to PHARMAC Board or its delegate) include information on how the decision aligns with the nine decision criteria.
Measure: Decisions on more than 90% of line items (excluding bids held open while awaiting Medsafe registration) will be made within 6 months of the tender closing.
Status: On track. 2014/15 tender decisions began to be made in February 2015. 138 line items were resolved by the end of March 2015. Of these 130 where tender awards. This result is 44% of line items (excluding bids held open while awaiting Medsafe registration) being resolved.
Measure: Hospital medical devices gross savings five-year NPV at least $4.74m.
Status: On track. Hospital medical devices gross savings five-year NPV at least $5.8m.
Measure: New investments made in hospital pharmaceuticals within financial limits agreed with DHB. Funding decisions supported by evidence and made using PHARMAC’s decision-making approach.
Status: On track. Savings and investments in hospital medicines being tracked and all PHARMAC funding decision papers (to PHARMAC Board or its delegate) include information on how the decision aligns with the nine decision criteria.
Output Class 2: Influencing medicines use
Measure: Amount of campaign materials distributed is greater than previous year.
Status: Not on track: To the end of Quarter 3 2014/15, there were 521 orders for campaign materials, with an average of 2.9 different ‘products’ per order (total orders in 2013/14 were 1,056 with an average of 2.6 products per order). This reflects an ongoing shift away from paper to electronic resources, for example, with many brand change materials only being provided for download rather than hardcopy.
A full year summary of distribution, including comparison with the previous year, will be provided at year-end.
Measure: Surveys of attendees show at least 90% of surveyed attendees rate their satisfaction with the Seminars at least 4 out of 5.
Status: On track: PHARMAC hosted four seminars in the period 1 January 2015 to 31 March 2015. Feedback from 96% of respondents rated the seminars at least 4 out of 5.
Measure: RFP completed and six presentations delivered through contracted partner to four different provider groups.
Status: On track: PHARMAC has reviewed and reworked the programme content to reflect changes to e-prescribing. Memoranda of Agreement (MoA) signed with three Whānau Ora Collectives and a fourth being negotiated, which will enable programme delivery from 2015. Māori Pharmacists’ Association identified as only provider with ability to deliver key course content through signed MOA.
Measure: Respond to low medicine stock reports, communicate effectively and take action as necessary to ensure patient needs for medicines are met.
Status: On track: There were 18 new low stock reports in the second quarter, 6 of which have been resolved
At the end of the third quarter PHARMAC was monitoring or actively managing 32 low stock reports.
Output Class 3: Providing policy advice and support
Measure: An average survey score of at least 4.5 in each area.
Status: This survey is completed annually at year-end and reported in the final quarter report.
Measure: All fund use is in accordance with PHARMAC policy.
Status: On track. A payment of $25 million was made to DHBs in relation to Combined Pharmaceuticals on 25 March 2015, which is part of cash payable for 2014/15 rebates.
Last updated: 4 February 2016